← boardnext 2026-11next 2027-01next 2027-05next 2027-09next 2028-04next 2030-11-30
RCUS
Arcus Biosciences, Inc.distress 5/10 · elevated risk$30.48+2%today-2% from 52w high
Oncology 5
Lead: Advanced Cancer · target TIGIT
Revenue
$17M
Liquidity
$201M
Runway
0.4 yrs
Shares 1y
+18%
Price & events
+32.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.7%
1D
+14.4%
1W
+8.1%
1M
+21.3%
3M
+37.7%
6M
+212.6%
1Y
+108.7%
2Y
-7.2%
5Y
+16.5%
All
Overview
- Market Cap
- $3.83B
- Enterprise Value
- $3.73B
- Volume
- 66.93K
- 52 Week Range
- $9.03 – $31.08
- Total Shares
- 125.77M
- Float Shares
- 88.98M
- Short %
- 16.54%
- % Held by Insiders
- 29.15%
- % Held by Institutions
- 72.33%
- RVOL
- 0.05x
- Beta
- 0.80
Pipeline stages · 7 programs
AB801, Docetaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Domvanalimab, Zimberelimab, Carboplatin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AB680, Zimberelimab, Nab-paclitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AB598, Zimberelimab, Fluorouracil
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
casdatifan, Cabozantinib, Zimberelimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Quemliclustat, Nab-paclitaxel, Gemcitabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AB308, Zimberelimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 15 trials · 8 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11 Estimated 50% readout ~2026-12-01 | Phase 1 | AB801, Docetaxel | Advanced Cancer | — | active not recruiting |
| 2027-01 Estimated 50% readout ~2027-02-15 | Phase 2 | Domvanalimab, Quemliclustat, Zimberelimab | Gastrointestinal Tract Malignancies | — | active not recruiting |
| 2027-05 Estimated 50% readout ~2027-06-15 | Phase 2 | Domvanalimab, Zimberelimab, Carboplatin | Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer | — | active not recruiting |
| 2027-05 Estimated 50% readout ~2027-05-31 | Phase 1 | AB680, Zimberelimab, Nab-paclitaxel | Advanced Pancreatic Cancer | — | active not recruiting |
| 2027-09 Estimated 50% readout ~2027-10-01 | Phase 1 | AB598, Zimberelimab, Fluorouracil | Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC) | — | active not recruiting |
Show all 15 trials · 10 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-04 Estimated 50% readout ~2028-06-15 | Phase 3 | Casdatifan, Cabozantinib | Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | — | recruiting |
| 2029-03 Estimated 50% readout ~2029-03-31 | Phase 1 | casdatifan, Cabozantinib, Zimberelimab | Clear Cell Renal Cell Carcinoma, Solid Tumors | — | recruiting |
| 2030-11-30 Estimated 50% readout ~2031-02-13 | Phase 3 | Quemliclustat, Nab-paclitaxel, Gemcitabine | Metastatic Pancreatic Ductal Adenocarcinoma | — | active not recruiting |
| 2026-06 | Phase 3 | Domvanalimab, Zimberelimab, Capecitabine | Advanced Upper Gastrointestinal Tract Adenocarcinoma | 1040 | active not recruiting |
| 2026-04-06 | Phase 1 | Quemliclustat | Healthy Participants | 8 | completed |
| 2025-10-18 | Phase 1 | Casdatifan, Itraconazole, Phenytoin | Healthy Participants | 14 | completed |
| 2025-09-05 | Phase 1/2 | AB680, Etrumadenant, Zimberelimab | Metastatic Colorectal Cancer | 227 | completed |
| 2025-08-25 | Phase 1 | AB308, Zimberelimab | Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer | 94 | completed |
| 2025-07-09 | Phase 2 | Domvanalimab, Etrumadenant, Zimberelimab | Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer | 151 | completed |
| 2025-01-23 | Phase 1 | Domvanalimab, Zimberelimab | Solid Tumor, Unspecified, Adult | 75 | completed |
Catalyst news & presentations · 8
- 2026Guided 40%trial initiationsecondaryMRGPRX2 inhibitor · expected to enter clinic in 2026SEC 8-K
- in 2026Guided 40%trial initiationsecondarymultiple programs · First clinical study for I&I programs expected in 2026.SEC 8-K
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-04-20partnershipGilead does not make option continuation payment; option rights end July 14, 2026.SEC 8-K
- 2026-04-20trial discontinueddomvanalimab, zimberelimab · Phase 2 EDGE-Lung discontinued along with STAR-121.SEC 8-K
- 2025-12-12trial discontinueddomvanalimab · Phase 3 STAR-221 and Phase 2 EDGE-Gastric discontinued due to futilitySEC 8-K
- 2025-02-18withdrawalcasdatifan · Gilead declined to exercise exclusive option, returning full global rights (except Taiho territory)SEC 8-K
- October 24, 2024conferencedata presentationsecondaryPhase 1/2casdatifan · Interim analysis of 100mg cohort from ARC-20 trialSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $36 (+17% upside) · 12 analysts
- 2026-07-20HC Wainwright & Co.Buy
- 2026-06-04LifeSci CapitalOutperform
- 2026-05-11Morgan StanleyEqual-Weight
- 2026-05-07Goldman SachsBuy
- 2026-04-02WedbushOutperform
- 2026-03-05CitigroupBuy
Competitors — TIGIT
- GILDGILEAD SCIENCES, INC.$159.5B · D2
Recent news
- 2026-07-23Arcus Biosciences (RCUS) Partners with Summit Therapeutics for K - GuruFocus
- 2026-07-22Arcus Biosciences (RCUS) Forms Clinical Supply Agreement with AV - GuruFocus
- 2026-07-22Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients - Business Wire
- 2026-07-22Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer - Business Wire
- 2026-07-22Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer - Business Wire
- 2026-07-22Arcus Biosciences to host Q2 2026 financial results call - scanx.trade
- 2026-07-21Arcus Biosciences to Discuss Cancer and Autoimmune Pipeline Aug. 5 - Stock Titan
- 2026-07-21Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates - Business Wire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.